Clinical Trial Update: A Phase II Trial of Poly-ICLC for Low-Grade Gliomas [Phase 2]

View source ↗

Summary

A terminated Phase II trial evaluating poly-ICLC for low-grade gliomas in NF1 patients has posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Low-grade Glioma
• Neurofibromatosis Type

Drugs mentioned

• Hiltonol (poly-ICLC) (poly-ICLC)

Snippet

Sponsor: University of Alabama at Birmingham | Conditions: NF1, Low-grade Glioma | Phase 2 | Status: TERMINATED | Results posted: 2025-03-21